Rosetta Genomics Ltd. is engaged in developing and commercializing new diagnostic tests based on various genomics markers, including deoxyribonucleic acid (DNA), micro ribonucleic acid (microRNA) and protein biomarkers and using various technologies, including, Quantitative polymerase chain reaction (qPCR), microarrays, Next Generation Sequencing (NGS) and Fluorescence In Situ Hybridization (FISH). It is marketing and selling over four diagnostic tests based on its microRNA technologies, which include RosettaGX Cancer Origin, mi-LUNG, mi-KIDNEY and RosettaGX Reveal. Its therapeutic pipeline consists of the projects, which include Rimonim Consortium and Magneton Project. It focuses on developing diagnostic assay, RosettaGX Reveal V2. It is also focusing on developing Bladder cancer risk stratification. Its PersonalizeDx is focused on the detection of genomic changes through FISH technology, which helps to detect cancer.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Laboratories & Research
- Sub-Industry: N/A
- Symbol: NASDAQ:ROSG
- CUSIP: N/A
- Web: www.rosettagenomics.com
- Market Cap: $3.21 million
- Outstanding Shares: 1,868,000
- 50 Day Moving Avg: $2.36
- 200 Day Moving Avg: $5.13
- 52 Week Range: $1.40 - $18.60
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -0.43
- P/E Growth: -0.02
- Annual Revenue: $9.23 million
- Price / Sales: 0.35
- Book Value: $2.40 per share
- Price / Book: 0.72
- EBIDTA: ($14,760,000.00)
- Net Margins: -167.32%
- Return on Equity: -127.01%
- Return on Assets: -103.27%
- Debt-to-Equity Ratio: 0.01%
- Current Ratio: 2.70%
- Quick Ratio: 2.70%
- Average Volume: 131,461 shs.
- Beta: -5.34
- Short Ratio: 0.55
Frequently Asked Questions for Rosetta Genomics (NASDAQ:ROSG)
What is Rosetta Genomics' stock symbol?
Rosetta Genomics trades on the NASDAQ under the ticker symbol "ROSG."
How were Rosetta Genomics' earnings last quarter?
Rosetta Genomics Ltd. (NASDAQ:ROSG) released its quarterly earnings data on Thursday, May, 19th. The company reported ($0.18) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.16) by $0.02. The firm had revenue of $2.60 million for the quarter, compared to the consensus estimate of $3.36 million. Rosetta Genomics had a negative net margin of 167.32% and a negative return on equity of 127.01%. View Rosetta Genomics' Earnings History.
Where is Rosetta Genomics' stock going? Where will Rosetta Genomics' stock price be in 2017?
2 analysts have issued 1-year price objectives for Rosetta Genomics' shares. Their forecasts range from $0.82 to $3.50. On average, they expect Rosetta Genomics' share price to reach $2.16 in the next year. View Analyst Ratings for Rosetta Genomics.
Who are some of Rosetta Genomics' key competitors?
Some companies that are related to Rosetta Genomics include Strata Skin Sciences (SSKN), Ampliphi Biosciences Corp (APHB), Acura Pharmaceuticals (ACUR), Sunshine Heart (SSH), Opexa Therapeutics (OPXA), Neurometrix (NURO), InspireMD (NSPR), Prana Biotechnology Limited (PRAN), Delcath Systems (DCTH), Affymax (AFFY), Dextera Surgical (DXTR), Adeptus Health (ADPT), Aegerion Pharmaceuticals (AEGR), Air Methods Corp (AIRM), Alphatec Holdings (ATEC), Ariad Pharmaceuticals (ARIA), Caladrius Biosciences (CLBS) and Celator Pharmaceuticals (CPXX).
Who owns Rosetta Genomics stock?
Who sold Rosetta Genomics stock? Who is selling Rosetta Genomics stock?
How do I buy Rosetta Genomics stock?
Shares of Rosetta Genomics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Rosetta Genomics stock cost?
One share of Rosetta Genomics stock can currently be purchased for approximately $1.72.
Earnings History for Rosetta Genomics (NASDAQ:ROSG)Earnings History by Quarter for Rosetta Genomics (NASDAQ:ROSG)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|9/26/2016||Q216||($0.17)||($0.16)||$2.89 million||$2.41 million||View||Listen|
|5/19/2016||Q116||($0.16)||($0.18)||$3.36 million||$2.60 million||View||Listen|
|3/23/2016||Q415||($0.33)||($0.14)||$3.50 million||$3.60 million||View||Listen|
Earnings Estimates for Rosetta Genomics (NASDAQ:ROSG)
Current Year EPS Consensus Estimate: $-5.64 EPS
Next Year EPS Consensus Estimate: $-3.96 EPS
Dividend History for Rosetta Genomics (NASDAQ:ROSG)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Rosetta Genomics (NASDAQ:ROSG)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Rosetta Genomics (NASDAQ:ROSG)
Latest Headlines for Rosetta Genomics (NASDAQ:ROSG)
Rosetta Genomics (ROSG) Chart for Wednesday, May, 24, 2017